The Journal of Addiction Medicine Publishes Patient-centered Outcomes from the Phase 3 Study of SUBLOCADE™ (Buprenorphine Extended-Release) Injection in Patients with Moderate to Severe Opioid Use Disorder (OUD)
Advertisement
Six monthly injections of SUBLOCADE™ improved patient health status and health-related quality of life compared to placebo in 24-week pivotal trial